I am deeply honored to be the recipient of the 2018 Gerhard Levy Distinguished Lectureship. Dr. Levy was a hero of mine and a pioneer in the field of biopharmaceutics, the “father” of pharmacodynamics, and an innovative contributor to the field of pharmacokinetics and clinical pharmacokinetics.
ROCHELLE, Va. (PRWEB) October 03, 2018
NDA Partners announced today that its Chairman, Carl Peck, MD, has been awarded the 2018 Gerhard Levy Distinguished Lectureship by the Department of Pharmaceutical Sciences, State University of New York at Buffalo. Dr. Peck will present his lecture entitled “Can We Abandon the p-value?”, in the Series in Pharmaceutical Sciences at the University at Buffalo on October 22, 2018.
The Distinguished Lectureship was established in 2001 by the Department of Pharmaceutical Sciences in honor of the late Dr. Gerhard Levy, Distinguished Professor (Emeritus), a widely recognized pioneer and principal contributor in the fields of biopharmaceuticals, pharmacokinetics, clinical pharmacokinetics, and pharmacodynamics.
“I am deeply honored to be the recipient of the 2018 Gerhard Levy Distinguished Lectureship. Dr. Levy was a hero of mine and a pioneer in the field of biopharmaceutics, the “father” of pharmacodynamics, and an innovative contributor to the field of pharmacokinetics and clinical pharmacokinetics,” said Dr. Peck.
As a Colonel in the US Army Medical Department, Dr. Peck founded and directed the Division of Clinical Pharmacology as Professor, Departments of Medicine and Pharmacology, Uniformed Services University, Bethesda, Maryland during 1980 to 1987. In 1987, FDA Commissioner Frank Young appointed Dr. Peck to be Director, Center for Drug Evaluation & Research (CDER), a national leadership position that he held until his retirement from government service in 1993. He was promoted to Assistant Surgeon General of the United States in the Public Health Service in October 1990. During 1994, Dr. Peck lectured as “Boerhaave” Professor of Clinical Drug Research at Leiden University (The Netherlands). Dr. Peck was the founding Director of the Center for Drug Development Science at Georgetown University Medical Center, where he served as Professor of Pharmacology from 1994 to 2003.
In 1999, Commissioner Jane Henney presented Dr. Peck with the FDA Distinguished Alumnus Award. Sweden’s University of Uppsala conferred an Honorary Doctorate degree (Doctor Honoris Causa) in January 2002 in recognition of “outstanding contributions to the science of drug development.” In 2012, he received the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Gary Neal Prize for Innovation in Drug Development and in 2017, the Sheiner-Beal Pharmacometrics Award, which was named in part after one of NDA Partners original founders, the late Professor Lewis Sheiner.
Appointed Adjunct Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California at San Francisco (UCSF) in 2004, Dr. Peck and colleagues founded the ongoing UCSF American Course in Drug Development and Regulatory Science in 2007. Dr. Peck is an author of more than 150 original research papers, chapters, and books. He serves on numerous scientific advisory boards to academic, industry and government institutions, and is a member of several boards of directors.
About NDA Partners
NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Earle Martin, Chief Executive Officer